Online inquiry

IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11484MR)

This product GTTS-WQ11484MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MET gene. The antibody can be applied in Colorectal Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000245.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4233
UniProt ID P08581
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11484MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8500MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA hu1124
GTTS-WQ4531MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-936558
GTTS-WQ5850MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ13533MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRX-003
GTTS-WQ3335MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AT-001
GTTS-WQ2007MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AGT-181
GTTS-WQ1557MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACE-041
GTTS-WQ10033MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA L19-131 I
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW